British pharma giant 'AstraZeneca' all set to roll out COVID-19 vaccine in September


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ british-pharma-astrazeneca-covid19-vaccine-september
The company is partnering up with Oxford University, which has pioneered the vaccine.

British pharma giant AstraZeneca is "on track" to start rolling out up to two billion doses of a COVID-19 vaccine in September if the ongoing trials prove to be a success, its Chief executive said on Friday.

The company is partnering up with Oxford University, which has pioneered the vaccine, and is already in the process of manufacturing doses before applying for the final regulatory approval once testing is finished in the coming months.

"So far we're still on track. We are starting to manufacture this vaccine right now, and we have to have it ready to be used by the time we have the results," AstraZeneca Chief executive Pascal Soriot told BBC radio. Our present assumption is that we will have the data by the end of the summer, by August, so in September we should know whether we have an effective vaccine or not."

The firm announced this week that it had entered into an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India to double the production capacity of the COVID-19 vaccine to two billion doses.

The partnership with the Indian Institute, one of the world's largest vaccine manufacturers, will prove beneficial in supplying it to a large number of low- and middle-income countries.
AstraZeneca has established individual supply chains for the vaccine in Europe, the United States, India and is also on the lookout to set up production in China, Soriot said.
He added that AstraZeneca, which is taking the responsibility of the work on a non-profit basis, could lose money if trials turn out to be disappointing.

But he also mentioned that the company was sharing the financial risk with organizations such as CEPI.

"We're manufacturing indeed at risk and that's the only way to have the vaccine ready to go if it works," he added.

Oxford University began the initial phase trials of its COVID-19 vaccine with hundreds of volunteers in April, and is now increasing the no. of participants to 10,000 participants.
It announced last month that they were "progressing very well".

Researchers announced recently that they will also start tests in mid-June in Brazil, the first country outside Britain to participate in the study, as the South American country's virus infection rate keeps increasing while the UK's falls.

Tags : #AstraZeneca #COVID-19 #OxfordUniversity

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026